Therapeutic targeting of ITGA1 delayed retinoblastoma progression through suppression of STAT3 signaling

Area of Science:

• Oncology
• Molecular Biology
• Ophthalmology

Background:

• Retinoblastoma (Rb) is the most common primary intraocular malignancy in children.
• Integrins are implicated as critical regulators in cancer progression.

Purpose of the Study:

• To investigate the functional roles and therapeutic potential of integrin alpha 1 (ITGA1) in retinoblastoma (Rb) pathogenesis.
• To explore ITGA1 as a potential therapeutic target for Rb.

Main Methods:

• Bioinformatics analysis of the GSE224022 dataset to identify differentially expressed genes in Rb tissues.
• Investigated the effects of ITGA1 knockdown and pharmacological inhibition (obtustatin) on Y79 Rb cells.
• Transcriptome analysis and western blot to identify downstream signaling pathways.
• In vivo studies using a murine xenograft model.

Main Results:

• ITGA1 and ITGB1 were significantly overexpressed in Rb specimens and Y79 cells.
• ITGA1 knockdown or obtustatin treatment inhibited Y79 cell proliferation, migration, and clonogenicity.
• STAT3 was identified as a key downstream mediator of ITGA1 signaling.
• STAT3 agonist (ML115) partially rescued the inhibitory effects of ITGA1 suppression.
• ITGA1 knockdown significantly delayed tumor growth in a murine xenograft model.

Conclusions:

• ITGA1 plays a critical role in Rb cell proliferation and migration.
• Targeting ITGA1, potentially through inhibition or knockdown, demonstrates therapeutic potential for retinoblastoma.
• The ITGA1-STAT3 axis represents a promising therapeutic strategy for Rb treatment.